Press coverage about Ionis Pharmaceuticals (NASDAQ:IONS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.9146265088961 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis (prnewswire.com)
- Akcea Convenes First FCS Global Connection Summit (feeds.benzinga.com)
- Ionis Pharmaceuticals (IONS) Downgraded to D+ at TheStreet (americanbankingnews.com)
- Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders (finance.yahoo.com)
IONS has been the topic of several research reports. BidaskClub raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. TheStreet downgraded shares of Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Tuesday, February 27th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Stifel Nicolaus raised their price target on shares of Ionis Pharmaceuticals from $55.00 to $57.00 and gave the stock a “hold” rating in a research note on Wednesday, February 28th. Finally, ValuEngine raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 8th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $51.12.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.10. Ionis Pharmaceuticals had a negative net margin of 1.18% and a negative return on equity of 1.94%. The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $126.38 million. During the same period last year, the business earned $0.33 earnings per share. Ionis Pharmaceuticals’s revenue was up 7.5% compared to the same quarter last year. research analysts anticipate that Ionis Pharmaceuticals will post -0.13 earnings per share for the current fiscal year.
In related news, Chairman Stanley T. Crooke sold 22,000 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total transaction of $1,100,220.00. Following the completion of the sale, the chairman now directly owns 58,014 shares in the company, valued at $2,901,280.14. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Joseph Klein III sold 3,000 shares of the firm’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $50.56, for a total transaction of $151,680.00. Following the sale, the director now owns 12,939 shares of the company’s stock, valued at $654,195.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 108,635 shares of company stock valued at $5,615,581. 2.13% of the stock is owned by company insiders.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.